Use of an IL1-receptor antagonist to prevent the progression of tendinopathy in a rat model

ABSTRACT This study evaluated if inhibiting IL1‐β activity with an IL1‐receptor antagonist (IL1‐RA) will prevent pathologic changes commonly seen in tendinopathy. Thirty‐six Sprague–Dawley retired‐breeder rats were divided into three groups having weekly bilateral patellar tendon injections: CON (0....

Full description

Saved in:
Bibliographic Details
Published in:Journal of orthopaedic research 2016-04, Vol.34 (4), p.616-622
Main Authors: Berkoff, David J., Kallianos, Steven A., Eskildsen, Scott M., Weinhold, Paul S.
Format: Article
Language:English
Subjects:
Animals
Antirheumatic Agents - pharmacology
Antirheumatic Agents - therapeutic use
Carrageenan
Disease Models, Animal
Disease Progression
Drug Evaluation, Preclinical
Female
IL1
inflammatory cytokine
Interleukin 1 Receptor Antagonist Protein - pharmacology
Interleukin 1 Receptor Antagonist Protein - therapeutic use
patellar tendon
Random Allocation
Rats, Sprague-Dawley
Receptors, Interleukin-1 - antagonists & inhibitors
Tendinopathy - drug therapy
tendon inflammation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT This study evaluated if inhibiting IL1‐β activity with an IL1‐receptor antagonist (IL1‐RA) will prevent pathologic changes commonly seen in tendinopathy. Thirty‐six Sprague–Dawley retired‐breeder rats were divided into three groups having weekly bilateral patellar tendon injections: CON (0.1 ml Saline), CAR (0.1 ml 2% carrageenan), IL1‐RA (0.1 ml 2% CAR plus 0.94 mg of the IL1‐RA, 2.5 mg/kg). Carrageenan was used to establish tendinopathy in two groups due to its ability to develop tendinopathy in prior studies. Animals were euthanized 3 weeks after initial injection. The CAR group demonstrated significantly (p 
ISSN:0736-0266
1554-527X
DOI:10.1002/jor.23057